Human atrial repolarization: effects of sinus rate, pacing and drugs on the surface electrocardiogram.
OBJECTIVE
We studied the effects of rate and some cardioactive drugs on the atrial surface electrocardiogram (ECG).


BACKGROUND
In atrioventricular block, atrial surface ECG is unmasked. The effect of rate alone permits detection of the effect of other exogenous stimulations such as drugs in the presence of rate alterations.


METHODS
High fidelity, high gain ECG leads I, II and III were recorded from 51 patients with heart block. Durations of P and Ta waves and the total PTa interval were measured from nonconducted atrial events.


RESULTS
No relationship was found between sinus cycle length and PTa, P or Ta in 31 patients. In 20 patients, progressively decreasing the atrial pacing cycle length from 853 ms to 381 ms resulted in a linear reduction of the PTa interval from 444 to 291 ms (rho = 0.76, slope = 0.24). This was largely due to shortening of Ta. A linear rate correction formula was derived: corrected PTa = PTa - 0.24 (PP - 1000). Atropine (0.02 mg/kg) shortened the PP interval (p < 0.001) and the PTa interval (p < 0.01). Propranolol (0.1 mg/kg) prolonged the PP interval (p < 0.001) but did not alter the PTa interval. Neither disopyramide (2.0 mg/kg) nor flecainide acetate (2.0 mg/kg) altered the PP interval, but both prolonged the PTa interval (p < 0.001). This was largely due to P wave lengthening after flecainide (p < 0.001) and to Ta prolongation after disopyramide (p < 0.001).


CONCLUSIONS
In heart block, PTa, P and Ta waves can be measured reliably. The effects of pacing and some antiarrhythmic drugs on the atrial myocardium are similar to those known at the ventricular level.
Debbas
N M
NM
Department of Cardiology, Cliniques Universitaires St Luc, UCL, Brussels, Belgium. debbas@card.ucl.ac.be
Jackson
S H
SH
de Jonghe
D
D
Robert
A
A
Camm
A J
AJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D004206:Disopyramide / Q000008:administration & dosage / Q000627:therapeutic use; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005424:Flecainide / Q000008:administration & dosage / Q000627:therapeutic use; D006325:Heart Atria / Q000187:drug effects / Q000503:physiopathology*; D006327:Heart Block / Q000503:physiopathology / Q000628:therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use; D015203:Reproducibility of Results